Evidence map›Paper›PMID 38424422›Full record

ArticleCurrent radiopharmaceuticals2024

"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant

Juliette Fouillet, Charlotte Donzé, Emmanuel Deshayes, Lore Santoro, Léa Rubira, Cyril Fersing

Open access · hybridAbstract read
In one paragraph

Article in Current radiopharmaceuticals, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Tailored Reaction Conditions and Automated Radiolabeling of [International journal of molecular sciences · 2025
    Article
  2. Pharmaceutics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Juliette FouilletNuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.ORCID 0009-0009-6778-259X
Charlotte DonzéNuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.ORCID 0009-0004-9223-1558
Emmanuel DeshayesNuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.ORCID 0000-0002-8408-4947
Lore SantoroNuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.ORCID 0000-0002-8935-1450
Léa RubiraNuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.ORCID 0000-0002-6343-7811
Cyril FersingNuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.ORCID 0000-0002-4455-4641
Université de Montpellier · FRInserm · FRÉcole Nationale Supérieure de Chimie de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate-specific membrane antigen (PSMA) is an ideal target for molecular imaging and targeted radionuclide therapy in prostate cancer. Consequently, various PSMA ligands were developed. Some of these molecules are functionalized with a chelator that can host radiometals, such as

objectiveTo design a single automated radiolabeling protocol for the GMP-compliant preparation of [

methodsA GAIA

results[

conclusionA single automated radiolabeling method on the GAIA

Indexed as

Gallium RadioisotopesHeterocyclic Compounds, 1-RingRadiopharmaceuticalsAntigens, SurfaceAutomationChromatography, High Pressure LiquidDipeptidesGallium IsotopesGlutamate Carboxypeptidase IIHumansIsotope LabelingLigandsMaleProstate-Specific AntigenProstatic NeoplasmsAntigens, SurfaceDipeptidesFOLH1 protein, humangallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLigandsProstate-Specific AntigenPSMA-11PSMA-617Radiopharmaceuticals68Gaautomated synthesisPET imagingprostate cancerPSMA-11PSMA-617PSMA-I&Tradiopharmacy.

Identifiers

PMID38424422
PMCPMC11348474
OpenAlexW4392352677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.